Wall Street analysts that cover Cidara Therapeutics Inc (NASDAQ:CDTX) are anticipating the company to post earnings per share of $-0.78 on a consensus basis for the quarter. The street is estimating that the report will be issued on or about 2017-03-17. This number comes from analysts that Zacks Research has included in their consensus estimate. This number may differ from other data providers that provide consensus estimates. For the period ending on 2016-09-30, the company reported a quarterly EPS of $-0.88. The actual reported number came in $-0.02 away from the consensus estimate. The resulting surprise factor was -2.33%.
In taking a look at where analysts believe Cidara Therapeutics Inc (NASDAQ:CDTX) is headed, the covering brokerages have a one year target price of $19.916 on the shares. This is based on the 6 analysts polled by Zacks Research. The analyst with the most aggressive viewpoint sees the stock heading towards $25 within the next 12 months while the most bearish sees the shares going to $10.5 in that same timeframe. The most recent analyst revision occurred on 2016-12-21. Depending on the brokerage firm, analysts on the sell-side use alternate terminology to describe their Buy/Sell recommendations.
Retail investors not familiar with a particular firms reports could find the recommendations difficult to understand. As a result, Zacks offers an analyst brokerage rating (ABR) which simplifies the recommendations into a 1 to 5 sliding scale where one represents a Strong Buy and 5 indicates a Strong Sell. Cidara Therapeutics Inc (NASDAQ:CDTX) currently has an ABR 1.67. This is the average recommendation based on the 6 analysts polled.
Please note that the data derived in this report is from Zacks Research. This is not a recommendation to Buy or Sell shares of Cidara Therapeutics Inc. The author of this article does not hold any position in the company. Investors should conduct their own thorough research before buying or selling equities.